cardamine: I get the concern that you and many other board members share regarding the likelihood of changes at the FDA, but I will withhold judgment long enough to give Dr Marty McKary, the newly confirmed FDA Commissioner, a chance to establish his policy prerogatives.

Dr McKary is an oncology surgeon from Johns Hopkins Hospital, and has preached rigorous science based decision making processes. Given how the previous FDA has treated Leronlimab, I'm more than curious to see how this new umpire calls balls and strikes when Leronlimab comes to the plate.